Effects of coating on the release profile of drug combination from hydrophilic matrix pellets
AbstractIn this work zinc sulfate, ferrous sulfate and ascorbic acid was formulated on the same pellet by combination
pelletization technique and their and in vitro dissolution studies were performed by using United States
Pharmacopoeia (USP) apparatus type II. In addition, effect of different types of polymers, formulation
variables and variations in coating composition on the release of drug were studied. The desired release
profile for ferrous sulfate was 35% for 1st hour, 45-75% for 2nd hour and 60-85% for third hour and not less
than 85% for 4th hour. The release rate controlling polymer used was various concentrations of Methoccel
K15M CR with different concentrations of Microcrystalline cellulose (Avicel PH 101). The maximum release
percentage of Ferrous Sulphate was obtained from 2.5 % of Methocel K15M CR and 30 % Avicel PH 101
containing pellets (F-4) and it was 92.32%. And the minimum release percentage of Ferrous Sulphate was
obtained from 10 % of Methocel K15M CR and 35.7% Avicel PH 101 containing pellets (F-1) and it was
86.36%. The release profile from other formulations containing 35.4% Methocel K 15M CR & 7.5% Avicel
(F-2) and 32% Methocel K 15M CR & 4% Avicel (F-3) were also within desired range. The effect of Eudragit
coating (enteric) and the presence of PEG and HPMC in the film coating composition on the drug release
were also investigated. Hydrophobic matrix pellets prepared using lower concentrations of Methocel K15M
CR were found to be best suited for modulating the delivery of the ferrous sulphate from the combination.
Key words: Non Pariel Seeds (NPS); Pan Coater; Ascorbic acid; Methocel K15M CR;
Pelletization; PEG; Avicel PH 101; Xanthan gum.
Stamford Journal of Pharmaceutical Sciences Vol.2(2) 2009: 53-58
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.